IFN-α Therapy Is Effective in Suppressing the Clinical Experimental Myasthenia Gravis

Journal of Immunology

Volumn 157, Issue 12, 1996, Pages 5675-5682

  Deng, Caishu ^a   Goluszko, Elzbieta ^a   Baron, Samuel ^a   Wu, Bo ^a   Christadoss, Premkumar ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; IMMUNOGLOBULIN CLASS; NICOTINIC RECEPTOR; RECOMBINANT INTERFERON;

ANIMAL; ARTICLE; C57BL MOUSE; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MOUSE; MUSCLE; MYASTHENIA GRAVIS;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; AUTOANTIBODIES; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN ISOTYPES; INTERFERON TYPE I, RECOMBINANT; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MUSCLES; MYASTHENIA GRAVIS; RECEPTORS, NICOTINIC;

EID: 0030589245     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Lindstrom, J., D. Shelton, and Y. Fuji. 1988. Myasthenia gravis. Adv. Immunol. 42:233.
2. Drachman, D. B. 1993. Myasthenia gravis. In Current Therapy in Neurologic Disease, 4th Ed. R. T. Johnson and J. W. Griffin, eds. Mosby-Year Book, St. Louis, pp. 379-384.
3. Johns, J. R. 1987. Long term corticosteroid treatment of myasthenia gravis. Ann. NY Acad. Sci. 505:568.
4. Tindall, R. S., J. T. Phillips, J. A. Rollins, L. Wells, and K. Hall. 1993. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. NY Acad. Sci. 681:539.
5. Matell, G. 1987. Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis. Ann. NY Acad. Sci. 505:588.
6. Wilensky, R., B. Dwyer, and R. F. Mayer. 1993. Relapses in patients with myasthenia gravis treated with azathioprine. Ann. NY Acad. Sci. 681:591.
7. Johnson, H. M., and S. Baron. 1976. The nature of the suppressive effect of interferon and interferon inducers on the in vitro immune response. Cell. Immunol. 25:106.
8. Baron, S., D. H. Coppenhaver, F. Dianzani, W. R. Fleischmann, Jr., T. K. Hughes, Jr., G. R. Klimpel, D. W. Niesel, G. J. Stanton, and S. K. Tyring. 1992. Interferon: Principles and Medical Application. The University of Texas Medical Branch Press, Galveston, pp. 1-624.
9. Stewart, T. A., B. Hultgren, X. Huang, S. Petts-Meek, J. Hully, and N. J. MacLachlan. 1993. Induction of type I diabetes by interferon-α in transgenic mice. Science 260:1942.
10. Chung, Y. H., and Y. K. Shong. 1993. Development of thyroid autoimmunity after administration of recombinant human interferon-α 2b for chronic viral hepatitis. Am. J. Gastroenterol. 88:244.
11. Peters, M., J. L. Ambras, A. Zheleznyak, D. Walling, and J. H. Hoofnagle. 1986. Effect of interferon-α on immunoglobulin synthesis by human B cells. J. Immunol. 137:3153.
12. Peters, M., D. M. Walling, K. Kelly, G. L. Davis, J. G. Waggoner, and J. H. Hoofnagle. 1986. Immunologic effects of interferon-α in man: treatment with human recombinant interferon-α suppresses in vitro immunoglobulin production in patients with chronic type B hepatitis. J. Immunol. 137:3147.
13. O'Gorman, M., and J. Oger. 1985. Reduced in vitro IgG secretion following in vivo injection of interferon in multiple sclerosis patients. Fed. Proc. 44:1923 (Abstr.).
14. Jacobs, L., J. O'Malley, A. Freeman, and R. Ekes. 1981. Intrathecal interferon reduces exacerbation of multiple sclerosis. Science 214:1026.
15. Jacobs, L., R. Herndon, A. Freeman, A. Cuetter, W. A. Smith, A. M. Salazar, P. A. Reese, R. Josefowicz, F. Husain, and R. Ekes. 1986. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbation of multiple sclerosis. Lancet 2:1411.
16. Knobler, R. L., J. I. Greenstein, K. P. Johnson, F. D. Lublin, H. S. Panitch, K. Conway, S. V. Grant-Gorsen, J. Muldoon, S. G. Marcus, J. C. Wallenberg, G. J. Williams, and C. N. Yoshizawa. 1993. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J. Interferon Res. 13:333.
17. The IFNβ Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind placebo-controlled trial. Neurology 43:655.
18. Inaba, K., M. Kitaura, T. Kato, Y. Watanabe, Y. Kawade, and S. Muramatsu. 1986. Contrasting effect of α/β and γ interferons on expression of macrophage Ia antigens. J. Exp. Med. 163:1030.
19. Kaul, R., M. Shenoy, E. Goluszko, and P. Christadoss. 1994. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 152:3152.
20. Shenoy, M., S. Baron, B. Wu, E. Goluszko, and P. Christadoss. 1995. IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis. J. Immunol. 154:6203.
21. Lindstrom, J., B. Einarson, and S. Tzartos. 1981. Production and assay of antibodies to acetylcholinc receptors. Methods Enzymol. 74:342.
22. Christadoss, P., J. M. Lindstrom, N. Talal, C. R. Duvic, A. Kalantri, and M. Shenoy. 1986. Immune response gene control of lymphocyte proliferation induced by acetylcholine receptor-specific helper factor derived from lymphocytes of myasthenic mice. J. Immunol. 137:1845.
23. Shenoy, M., M. Oshima, M. Z. Atassi, and P. Christadoss. 1993. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α146-162 of acetylcholine receptor. Clin. Immunol. Immunopathol. 66:230.
24. Shenoy, M., E. Goluszko, and P. Christadoss. 1994. The pathogenic role of acetylcholine receptor α chain epitope within α146-162 in the development of experimental autoimmune myasthenia gravis in C57BL/6J mice. Clin. Immunol. Immunopathol. 73:338.
25. Christadoss, P., and M. J. Dauphinee. 1986. Immunotherapy for myasthenia gravis: a murine model. J. Immunol. 136:2437.
26. Drachman, D. B. 1994. Myasthenia gravis. N. Engl. J. Med. 330:1797.
27. Drachman, D. B., R. N. Adams, L. F. Josifek, and S. G. Self. 1982. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N. Engl. J. Med. 307:769.
28. Christadoss, P., J. Lindstrom, S. Munro, and N. Talal. 1985. Muscle acetylcholine receptor loss in marine experimental autoimmune myasthenia gravis: correlated with cellular, humoral and clinical responses. J. Neuroimmunol. 8:29.
29. 125I-labelled human interferons alpha, beta and gamma: comparative receptor-binding data. J. Gen. Virol. 66:1149.